Floatz logo

Ny-Eso-1 Protein

Malignant Melanoma

Nina BhardwajvaccinePhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

450 Active assets in the Malignant Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Alpha-Interferon
Hoffmann-La Roche
Phase 2/3BB

View all 50 →

Same molecule, other indications

Ny-Eso-1 Protein is also rated in:

transitional cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
prostate cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →